Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 336

The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.

The α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy

Galili, Uri·2005·Immunology & Cell Biology

Abstract

The α‐gal epitope (Galα1‐3Galβ1‐(3)4GlcNAc‐R) is abundantly synthesized on glycolipids and glycoproteins of non‐primate mammals and New World monkeys by the glycosylation enzyme α1,3galactosyltransferase (α1,3GT). In humans, apes and Old World monkeys, this epitope is absent because the α1,3GT gene was inactivated in ancestral Old World primates. Instead, humans, apes and Old World monkeys produce the anti‐Gal antibody, which specifically interacts with α‐gal epitopes and which constitutes ∼1% of circulating immunoglobulins. Anti‐Gal has functioned as an immunological barrier, preventing the transplantation of pig organs into humans, because anti‐Gal binds to the α‐gal epitopes expressed on pig cells. The recent generation of α1,3GT knockout pigs that lack α‐gal epitopes has resulted in the elimination of this immunological barrier. Anti‐Gal can be exploited for clinical use in cancer immunotherapy by targeting autologous tumour vaccines to APC, thereby increasing their immunogenicity. Autologous intact tumour cells from haematological malignancies, or autologous tumour cell membranes from solid tumours are processed to express α‐gal epitopes by incubation with neuraminidase, recombinant α1,3GT and with uridine diphosphate galactose. Subsequent immunization with such autologous tumour vaccines results in in vivo opsonization by anti‐Gal IgG binding to these α‐gal epitopes. The interaction of the Fc portion of the vaccine‐bound anti‐Gal with Fcγ receptors of APC induces effective uptake of the vaccinating tumour cell membranes by the APC, followed by effective transport of the vaccinating tumour membranes to the regional lymph nodes, and processing and presentation of the tumour‐associated antigen (TAA) peptides. Activation of tumour‐specific T cells within the lymph nodes by autologous TAA peptides may elicit an immune response that in some patients will be potent enough to eradicate the residual tumour cells that remain after completion of standard therapy. A similar expression of α‐gal epitopes can be achieved by transduction of tumour cells with an adenovirus vector (or other vectors) containing the α1,3GT gene, thus enabling anti‐Gal‐mediated targeting of the vaccinating transduced cells to APC. Intratumoral delivery of the α1,3GT gene by various vectors results in the expression of α‐gal epitopes. Such expression of the xenograft carbohydrate phenotype is likely to induce anti‐Gal‐mediated destruction of the tumour lesion, similar to rejection of xenografts by this antibody. Opsonization of the destroyed tumour cell membranes by anti‐Gal IgG further targets them to APC, thus converting the tumour lesion, treated by the α1,3GT gene, into an in situ autologous tumour vaccine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1440-1711.2005.01366.x

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 125 references

Cited by

See all 336

Metadata

Authors
Galili, U.
Venue
Immunology & Cell Biology
Publisher
Wiley
Published
2005-10-21
Volume
83
Issue
6
Pages
674-686
ISSN
  • 0004-945X (ISSN-L)
  • 0818-9641
  • 1440-1711
OpenAlex
W2151173049
Cited by
336
References
125
FWCI
9.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy. https://app.cochat.ai/papers/10.1111/j.1440-1711.2005.01366.x
The paper
Galili, U. (2005). The α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy. Immunology & Cell Biology. https://doi.org/10.1111/j.1440-1711.2005.01366.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.